United States Renal Data System 2019 annual data report: epidemiology of kidney disease in the United States.

National Institutes of Health NIDDKD, Bethesda, MD ()Glassock RJ Delanaye P Rule AD.

Should the definition of CKD be changed to include age-adapted GFR criteria?.

YES. Kidney Int. 97: 34-37Levey AS Inker LA Coresh J.

Should the definition of CKD be changed to include age-adapted GFR criteria?": Con: the evaluation and management of CKD, not the definition, should be age-adapted.

Kidney Int. 97: 37-40Lambers Heerspink HJ Gansevoort RT

Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view.

Clin J Am Soc Nephrol. 10: 1079-1088Levey AS Gansevoort RT Coresh J Inker LA Heerspink HL Grams ME et al.

Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency.

Am J Kidney Dis. 75: 84-104

Rebuttal of the pro view: albuminuria is an appropriate therapeutic target in patients with CKD.

Clin J Am Soc Nephrol. 10: 1095-1098

Albuminuria is not an appropriate therapeutic target in patients with CKD: the con view.

Clin J Am Soc Nephrol. 10: 1089-1093Lambers Heerspink HJ Gansevoort RT

Rebuttal of the con view: albuminuria is an appropriate therapeutic target in patients with CKD.

Clin J Am Soc Nephrol. 10: 1099Gerstein HC Mann JF Yi Q Zinman B Dinneen SF Hoogwerf B et al.

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

JAMA. 286: 421-426Solomon SD Lin J Solomon CG Jablonski KA Rice MM Steffes M et al.

Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease.

Circulation. 116: 2687-2693Stehouwer CD Smulders YM.

Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms.

J Am Soc Nephrol. 17: 2106-2111

Microalbuminuria and cardiovascular disease.

Clin J Am Soc Nephrol. 2: 581-590de Zeeuw D Remuzzi G Parving HH Keane WF Zhang Z Shahinfar S et al.

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Circulation. 110: 921-927Ibsen H Olsen MH Wachtell K Borch-Johnsen K Lindholm LH Mogensen CE et al.

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.

Hypertension. 45: 198-202Li L Astor BC Lewis J Hu B Appel LJ Lipkowitz MS et al.

Longitudinal progression trajectory of GFR among patients with CKD.

Am J Kidney Dis. 59: 504-512Skupien J Warram JH Smiles AM Stanton RC Krolewski AS.

Patterns of estimated glomerular filtration rate decline leading to end-stage renal disease in type 1 diabetes.

Diabetes Care. 39: 2262-2269Weldegiorgis M de Zeeuw D Li L Parving HH Hou FF Remuzzi G et al.

Longitudinal estimated GFR trajectories in patients with and without type 2 diabetes and nephropathy.

Am J Kidney Dis. 71: 91-101Zinman B Wanner C Lachin JM Fitchett D Bluhmki E Hantel S et al.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

N Engl J Med. 373: 2117-2128

Summary of revisions: standards of medical care in diabetes-2020.

Diabetes Care. 43: S4-S6

Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease.

Kidney Int. 98: S1-115Perkovic V Jardine MJ Neal B Bompoint S Heerspink HJL Charytan DM et al.

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

N Engl J Med. 380: 2295-2306Packer M Anker SD Butler J Filippatos G Pocock SJ Carson P et al.

Cardiovascular and renal outcomes with empagliflozin in heart failure.

N Engl J Med. 383: 1413-1424Heerspink HJL Stefansson BV Correa-Rotter R Chertow GM Greene T Hou FF et al.

Dapagliflozin in patients with chronic kidney disease.

N Engl J Med. 383: 1436-1446Cannon CP Perkovic V Agarwal R Baldassarre J Bakris G Charytan DM et al.

Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial.

Circulation. 141: 407-410

Sodium-glucose co-transporters and their inhibition: clinical physiology.

Cell Metab. 26: 27-38

Risks associated with SGLT2 inhibitors: an overview.

Curr Drug Saf. 13: 84-91Neal B Perkovic V Mahaffey KW de Zeeuw D Fulcher G Erondu N et al.

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

N Engl J Med. 377: 644-657McMurray JJV Solomon SD Inzucchi SE Kober L Kosiborod MN Martinez FA et al.

Dapagliflozin in patients with heart failure and reduced ejection fraction.

N Engl J Med. 381: 1995-2008Cannon CP Pratley R Dagogo-Jack S Mancuso J Huyck S Masiukiewicz U et al.

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.

N Engl J Med. 383: 1425-1435Wanner C Inzucchi SE Lachin JM Fitchett D von Eynatten M Mattheus M et al.

Empagliflozin and progression of kidney disease in type 2 diabetes.

N Engl J Med. 375: 323-334Cherney DZ Perkins BA Soleymanlou N Maione M Lai V Lee A et al.

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

Circulation. 129: 587-597

Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?.

Circulation. 129: 542-544van Bommel EJM Muskiet MHA van Baar MJB Tonneijck L Smits MM Emanuel AL et al.

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.

Kidney Int. 97: 202-212Mudaliar S Alloju S Henry RR.

Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis.

Diabetes Care. 39: 1115-1122Osataphan S Macchi C Singhal G Chimene-Weiss J Sales V Kozuka C et al.

SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.

JCI Insight. 4e123130Onishi A Fu Y Patel R Darshi M Crespo-Masip M Huang W et al.

A role for tubular Na(+)/H(+) exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.

Am J Physiol Renal Physiol. 319: F712-F728

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

Clin J Am Soc Nephrol. 5: 133-141Forbes JM Cooper ME Oldfield MD Thomas MC.

Role of advanced glycation end products in diabetic nephropathy.

J Am Soc Nephrol. 14: S254-S258Suehiro A Uchida K Nakanishi M Wakabayashi I.

Measurement of urinary advanced glycation end-products (AGEs) using a fluorescence assay for metabolic syndrome-related screening tests.

Diabetes Metab Syndr. 10: S110-S113Zhang J Wei J Jiang S Xu L Wang L Cheng F et al.

Macula densa SGLT1-NOS1-tubuloglomerular feedback pathway, a new mechanism for glomerular hyperfiltration during hyperglycemia.

J Am Soc Nephrol. 30: 578-593Ruggenenti P Abbate M Ruggiero B Rota S Trillini M Aparicio C et al.

Renal and systemic effects of calorie restriction in patients with type 2 diabetes with abdominal obesity: a randomized controlled trial.

Diabetes. 66: 75-86

Back to the future: glomerular hyperfiltration and the diabetic kidney.

Diabetes. 66: 14-16Dickson LE Wagner MC Sandoval RM Molitoris BA.

The proximal tubule and albuminuria: really!.

J Am Soc Nephrol. 25: 443-453Muskiet MHA Tonneijck L Smits MM van Baar MJB Kramer MHH Hoorn EJ et al.

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.

Nat Rev Nephrol. 13: 605-628Garber AJ Handelsman Y Grunberger G Einhorn D Abrahamson MJ Barzilay JI et al.

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary.

Endocr Pract. 26: 107-139Gerstein HC Colhoun HM Dagenais GR Diaz R Lakshmanan M Pais P et al.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Lancet. 394: 121-130Marso SP Bain SC Consoli A Eliaschewitz FG Jodar E Leiter LA et al.

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.

N Engl J Med. 375: 1834-1844Marso SP Daniels GH Brown-Frandsen K Kristensen P Mann JF Nauck MA et al.

Liraglutide and cardiovascular outcomes in type 2 diabetes.

N Engl J Med. 375: 311-322Mann JFE Orsted DD Brown-Frandsen K Marso SP Poulter NR Rasmussen S et al.

Liraglutide and renal outcomes in type 2 diabetes.

N Engl J Med. 377: 839-848Gerstein HC Colhoun HM Dagenais GR Diaz R Lakshmanan M Pais P et al.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Lancet. 394: 131-138Tanaka T Higashijima Y Wada T Nangaku M.

The potential for renoprotection with incretin-based drugs.

Kidney Int. 86: 701-711

Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes.

Front Endocrinol (Lausanne). 10: 80Groop PH Cooper ME Perkovic V Hocher B Kanasaki K Haneda M et al.

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Diabetes Obes Metab. 19: 1610-1619Rosenstock J Perkovic V Johansen OE Cooper ME Kahn SE Marx N et al.

Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial.

JAMA. 321: 69-79Mosenzon O Leibowitz G Bhatt DL Cahn A Hirshberg B Wei C et al.

Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial.

Diabetes Care. 40: 69-76Pollock C Stefansson B Reyner D Rossing P Sjostrom CD Wheeler DC et al.

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Lancet Diabetes Endocrinol. 7: 429-441Bae JH Kim S Park EG Kim SG Hahn S Kim NH.

Effects of dipeptidyl peptidase-4 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis.

Endocrinol Metab (Seoul). 34: 80-92De Miguel C Speed JS Kasztan M Gohar EY Pollock DM.

Endothelin-1 and the kidney: new perspectives and recent findings.

Curr Opin Nephrol Hypertens. 25: 35-41Heerspink HJL Parving HH Andress DL Bakris G Correa-Rotter R Hou FF et al.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Lancet. 393: 1937-1947Mann JF Green D Jamerson K Ruilope LM Kuranoff SJ Littke T et al.

Avosentan for overt diabetic nephropathy.

J Am Soc Nephrol. 21: 527-535Johnson RJ Nakagawa T Jalal D Sanchez-Lozada LG Kang DH Ritz E.

Uric acid and chronic kidney disease: which is chasing which?.

Nephrol Dial Transplant. 28: 2221-2228Muiesan ML Agabiti-Rosei C Paini A Salvetti M.

Uric acid and cardiovascular disease: an update.

Eur Cardiol. 11: 54-59Doria A Galecki AT Spino C Pop-Busui R Cherney DZ Lingvay I et al.

Serum urate lowering with allopurinol and kidney function in type 1 diabetes.

N Engl J Med. 382: 2493-2503Agarwal R Kolkhof P Bakris G Bauersachs J Haller H Wada T et al.

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.

Eur Heart J. 42: 152-161Kolkhof P Nowack C Eitner F.

Nonsteroidal antagonists of the mineralocorticoid receptor.

Curr Opin Nephrol Hypertens. 24: 417-424Schrier RW Masoumi A Elhassan E.

Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.

Clin J Am Soc Nephrol. 5: 1132-1140Fried LF Emanuele N Zhang JH Brophy M Conner TA Duckworth W et al.

Combined angiotensin inhibition for the treatment of diabetic nephropathy.

N Engl J Med. 369: 1892-1903Investigators O Yusuf S Teo KK Pogue J Dyal L Copland I et al.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

N Engl J Med. 358: 1547-1559Bakris GL Agarwal R Anker SD Pitt B Ruilope LM Rossing P et al.

Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.

N Engl J Med. 383: 2219-2229Pei H Wang W Zhao D Wang L Su GH Zhao Z.

The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis.

Medicine (Baltimore). 97: e0254Bakris GL Pitt B Weir MR Freeman MW Mayo MR Garza D et al.

Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial.

JAMA. 314: 151-161Spinowitz BS Fishbane S Pergola PE Roger SD Lerma EV Butler J et al.

Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study.

Clin J Am Soc Nephrol. 14: 798-809Weir MR Bakris GL Bushinsky DA Mayo MR Garza D Stasiv Y et al.

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

N Engl J Med. 372: 211-221Bilous R Chaturvedi N Sjolie AK Fuller J Klein R Orchard T et al.

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

Ann Intern Med. 151 (): 11-20Mauer M Zinman B Gardiner R Suissa S Sinaiko A Strand T et al.

Renal and retinal effects of enalapril and losartan in type 1 diabetes.

N Engl J Med. 361: 40-51